Hair Regeneration in Androgenetic Alopecia

• Status: Active, not recruiting
• Trial end date: 2023-11-30
• Target enrollment: 0
• Participant gender: Male

Summary

This clinical trial study aims to compare the effectiveness and safety of secretome from ADSCs with minoxidil in AGA cases, to provide future reference or standard in the application of cell-based therapy and its derivatives in AGA cases. The subject of this study is androgenetic alopecia population. The main questions it aims to answer are:

• Is the secretome of ADSC's effective compared to minoxidil?

• Is the secretome of ADSC's safe compared to minoxidil?

• Is the combination of the secretome of ADSC's and minoxidil better in safety and effectiveness compared to secretome or minoxidil alone?

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dr. dr. Lili Legiawati, SpKK(K)
• Collaborators: Ministry of Education, Culture, Research, and Technology, Republic of Indonesia; PT. Kimia Farma (Persero) Tbk
• Treatments: Minoxidil

Criteria

Inclusion Criteria:

• Male patients aged 18-59 years

• Clinical presentation of AGA with Hamilton-Norwood Grade III-VI

• Willing to be a research subject, sign a consent form, and commit to regular follow-up visits

Exclusion Criteria:

• Hair loss other than AGA, including telogen effluvium, alopecia areata, trichotillomania, secondary syphilis, systemic lupus erythematosus hair loss due to chemotherapy, autoimmune conditions, or malignancies.

• Patients taking oral medications or vitamins aimed at increasing hair growth in the last month

• Patients applying topical medications aimed at increasing hair growth in the last 2 weeks

• Patients with active bacterial, viral, or fungal infections on the scalp

• Patients undergoing AGA therapy cosmetic procedures in the form of PRP injections, laser procedures, or micro-needling in the last 3 months